Accès gratuit
Numéro
Med Sci (Paris)
Volume 28, Numéro 4, Avril 2012
Page(s) 388 - 394
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2012284016
Publié en ligne 25 avril 2012
  1. Global measles mortality, 2000–2008. Morb Mortal Wkly Rep 2009 ; 58 : 1321–1326.
  2. Enders JF, Peebles TC. Propagation in tissue cultures of cytopathogenic agents from patients with measles. Proc Soc Exp Biol Med 1954 ; 86 : 277–286. [PubMed]
  3. Muhlebach MD, Mateo M, Sinn PL, et al. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 2011 ; 480 : 530–533. [PubMed]
  4. Noyce RS, Bondre DG, Ha MN, et al. Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus. PLoS Pathog 2011 ; 7 : e1002240. [CrossRef] [PubMed]
  5. Bluming AZ, Ziegler JL. Regression of Burkitt’s lymphoma in association with measles infection. Lancet 1971 ; 2 : 105–106. [CrossRef] [PubMed]
  6. Mota HC., Infantile Hodgkin’s disease: remission after measles. Br Med J 1973 ; 2 : 421. [CrossRef] [PubMed]
  7. Taqi AM, Abdurrahman MB, Yakubu AM, Fleming AF., Regression of Hodgkin’s disease after measles. Lancet 1981 ; 1 : 1112. [CrossRef]
  8. Zygiert Z., Hodgkin’s disease: remissions after measles.Lancet 1971 ; 1 : 593. [CrossRef] [PubMed]
  9. Heinzerling L, Kunzi V, Oberholzer PA, et al. Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. Blood 2005 ; 106 : 2287–2294. [CrossRef] [PubMed]
  10. Galanis E, Hartmann LC, Cliby WA, et al. Phase I Trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 2010 ; 70 : 875–882. [CrossRef] [PubMed]
  11. Dhiman N, Jacobson RM, Poland GA. Measles virus receptors: SLAM and CD46. Rev Med Virol 2004 ; 14 : 217–229. [CrossRef] [PubMed]
  12. Dorig RE, Marcil A, Chopra A, Richardson CD. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 1993 ; 75 : 295–305. [CrossRef] [PubMed]
  13. Anderson BD, Nakamura T, Russell SJ, Peng KW. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res 2004 ; 64 : 4919–4926. [CrossRef] [PubMed]
  14. Bossow S, Grossardt C, Temme A, et al. Armed and targeted measles virus for chemovirotherapy of pancreatic cancer. Cancer Gene Ther 2011 ; 18 : 598–608. [CrossRef] [PubMed]
  15. Ungerechts G, Springfeld C, Frenzke ME, et al. An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol Ther 2007 ; 15 : 1991–1997. [CrossRef] [PubMed]
  16. Ungerechts G, Springfeld C, Frenzke ME, et al. Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. Cancer Res 2007 ; 67 : 10939–10947. [CrossRef] [PubMed]
  17. Allen C, Vongpunsawad S, Nakamura T, et al. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Cancer Res 2006 ; 66 : 11840–11850. [CrossRef] [PubMed]
  18. Allen C, Paraskevakou G, Liu C, et al. Oncolytic measles virus strains in the treatment of gliomas. Expert Opin Biol Ther 2008 ; 8 : 213–220. [CrossRef] [PubMed]
  19. Liu C, Hasegawa K, Russell SJ, et al. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer. Prostate 2009 ; 69 : 1128–1141. [CrossRef] [PubMed]
  20. Springfeld C, von Messling V, Frenzke M, et al. Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res 2006 ; 66 : 7694–7700. [CrossRef] [PubMed]
  21. Leber MF, Bossow S, Leonard VH, et al. MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism. Mol Ther 2011 ; 19 : 1097–1106. [CrossRef]
  22. Morfin F, Beguin A, Lina B, Thouvenot D. Detection of measles vaccine in the throat of a vaccinated child. Vaccine 2002 ; 20 : 1541–1543. [CrossRef] [PubMed]
  23. Leonard VH, Sinn PL, Hodge G, et al. Measles virus blind to its epithelial cell receptor remains virulent in rhesus monkeys but cannot cross the airway epithelium and is not shed. J Clin Invest 2008 ; 118 : 2448–2458. [PubMed]
  24. Iankov ID, Blechacz B, Liu C, et al. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther 2007 ; 15 : 114–122. [CrossRef] [PubMed]
  25. Mader EK, Maeyama Y, Lin Y, et al. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res 2009 ; 15 : 7246–7255. [CrossRef] [PubMed]
  26. Liu C, Russell SJ, Peng KW. Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol Ther 2010 ; 18 : 1155–1164. [CrossRef] [PubMed]
  27. Lamfers ML, Fulci G, Gianni D, et al. Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. Mol Ther 2006 ; 14 : 779–788. [CrossRef] [PubMed]
  28. Myers RM, Greiner SM, Harvey ME, et al. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther 2007 ; 82 : 700–710. [CrossRef] [PubMed]
  29. Bitnun A, Shannon P, Durward A, et al. Measles inclusion-body encephalitis caused by the vaccine strain of measles virus. Clin Infect Dis 1999 ; 29 : 855–861. [CrossRef] [PubMed]
  30. Miest TS, Yaiw KC, Frenzke M, et al. Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis. Mol Ther 2011 ; 19 : 1813–1820. [CrossRef] [PubMed]
  31. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009 ; 27 : 5763–5771. [CrossRef] [PubMed]
  32. Park BH, Hwang T, Liu TC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008 ; 9 : 533–542. [CrossRef] [PubMed]
  33. Ottolino-Perry K, Diallo JS, Lichty BD, et al. Intelligent design: combination therapy with oncolytic viruses. Mol Ther 2010 ; 18 : 251–263. [CrossRef] [PubMed]
  34. Ungerechts G, Frenzke ME, Yaiw KC, et al. Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics. Gene Ther 2010 ; 17 : 1506–1516. [CrossRef] [PubMed]
  35. Touchefeu Y, Vassaux G, Harrington KJ. Oncolytic viruses in radiation oncology. Radiother Oncol 2011 ; 99 : 262–270. [CrossRef] [PubMed]
  36. Liu C, Sarkaria JN, Petell CA, et al. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Clin Cancer Res 2007 ; 13 : 7155–7165. [CrossRef] [PubMed]
  37. Dingli D, Peng KW, Harvey ME, et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004 ; 103 : 1641–1646. [CrossRef] [PubMed]
  38. Msaouel P, Iankov ID, Allen C, et al. Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Mol Ther 2009 ; 17 : 2041–2048. [CrossRef] [PubMed]
  39. Penheiter AR, Wegman TR, Classic KL, et al. Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer. Am J Roentgenol 2010 ; 195 : 341–349. [CrossRef]
  40. Mateo M, Lopez M. Nectine-4, une protéine clé pour la transmission du virus de la rougeole. Med Sci (Paris) 2012 ; 28 : 363–365. [CrossRef] [EDP Sciences] [PubMed]
  41. Lemay G. Apprivoiser nos ennemis pour en faire des alliés : la virothérapie anticancéreuse. Med Sci (Paris) 2012 ; 28 : 339–340. [CrossRef] [EDP Sciences] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.